The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Zymeworks BC Inc’s stock clocked out at $10.49, up 0.10% from its previous closing price of $10.48. In other words, the price has increased by $0.10 from its previous closing price. On the day, 0.41 million shares were traded. ZYME stock price reached its highest trading level at $10.59 during the session, while it also had its lowest trading level at $10.26.
Ratios:
To gain a deeper understanding of ZYME’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 7.01. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On January 04, 2023, H.C. Wainwright reiterated its Neutral rating and also upped its target price recommendation from $10 to $8.
Jefferies Upgraded its Hold to Buy on December 20, 2022, whereas the target price for the stock was revised from $7.70 to $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 05 ’24 when Galbraith Kenneth sold 18,198 shares for $10.65 per share. The transaction valued at 193,849 led to the insider holds 29,468 shares of the business.
Galbraith Kenneth sold 5,706 shares of ZYME for $63,996 on Jan 08 ’24. The Chair & CEO now owns 23,762 shares after completing the transaction at $11.22 per share. On Jan 05 ’24, another insider, Astle Christopher, who serves as the SVP & Chief Financial Officer of the company, sold 4,563 shares for $10.65 each. As a result, the insider received 48,606 and left with 7,934 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 745287232 and an Enterprise Value of 435229120. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.98 while its Price-to-Book (P/B) ratio in mrq is 1.84. Its current Enterprise Value per Revenue stands at 6.941 whereas that against EBITDA is -3.767.
Stock Price History:
Over the past 52 weeks, ZYME has reached a high of $13.14, while it has fallen to a 52-week low of $6.01. The 50-Day Moving Average of the stock is 9.61%, while the 200-Day Moving Average is calculated to be 8.26%.
Shares Statistics:
It appears that ZYME traded 651.09K shares on average per day over the past three months and 734990 shares per day over the past ten days. A total of 70.12M shares are outstanding, with a floating share count of 69.63M. Insiders hold about 2.78% of the company’s shares, while institutions hold 96.45% stake in the company. Shares short for ZYME as of 1722384000 were 3452695 with a Short Ratio of 5.30, compared to 1719532800 on 3269612. Therefore, it implies a Short% of Shares Outstanding of 3452695 and a Short% of Float of 5.52.
